Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3

descriptionPublicationkeyboard_double_arrow_right Article 01 May 2011Publisher:JLEJournal:European Journal of Dermatology, volume 21, pages 415-416 (issn: 1167-1122, eissn: 1952-4013,

Copyright policy )

Authors: Rodrigo CARVALHO; Paula MAIO; Daniela CUNHA; Isabel FREITAS; Ana AFONSO; Jorge CARDOSO;

doi: 10.1684/ejd.2011.1288

Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3

- Summary
- Metrics

Abstract

ejd.2011.1288 Auteur(s) : Rodrigo CARVALHO1 rodrigoaraujocarvalho@gmail.com, Paula MAIO1, Daniela CUNHA1, Isabel FREITAS1, Ana AFONSO2, Jorge CARDOSO1 1 Department of Dermatology and Venereology, Curry Cabral Hospital, Lisbon, Portugal 2 Department of Pathology, Curry Cabral Hospital, Lisbon, Portugal Reprints.: R. CARVALHO Pemphigus foliaceous (PF) is generally a benign autoimmune blistering disease, but in some patients lesions are severe with serious implications in life quality. We report a [...]

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average